Patritumab Plus Erlotinib in EGFR Wild-Type Advanced Non-Small Cell Lung Cancer: A 2-Part Phase 3 Study (HER3-Lung)

被引：0

作者：

Akerley, Wallace L. ^{[1
]}

Von Pawel, Joachim ^{[2
]}

Moritz, Berta ^{[3
]}

Zhang, Ling ^{[4
]}

Macintyre, Susan ^{[4
]}

Feng, Wenqin ^{[4
]}

Shuster, Dale ^{[4
]}

Chen, Shuquan ^{[4
]}

Copigneauxl, Catherine ^{[4
]}

Ares, Luis Paz ^{[5
]}

机构：

[1] Huntsman Canc Inst, Salt Lake City, UT USA

[2] Asklepios Fachkliniken, Gauting, Germany

[3] Cesar Cent European Soc Anticanc Drug Res, Vienna, Austria

[4] Daiichi Sankyo Pharma Dev, Edison, NJ USA

[5] Univ Hosp Virgen Del Rocio, Seville, Spain

来源：

关键词：

Advanced non-small cell lung cancer; Heregulin biomarker; Phase; 3; study; Patritumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-081

引用

页码：S429 / S429

页数：1